Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
Charts & Report
Charts and Graphs
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
2254.5000
-13.20
(
-0.58
%)
NSE
Jun 08, 2026
15:31 PM
Volume:
445.0K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
16 Feb 2026
US FDA Approval
2254.50
-0.58%
Result Update:Lupin
Buy:
Lupin Ltd.
by
Axis Direct
Target: 2460 | Target met
Target
Axis Direct
We recommend a BUY rating with a target price of Rs 2,460/share.
Lupin Ltd. is trading
below its 30 day SMA
of 2293.4
More from Lupin Ltd.
Recommended
CMR Green Tech, Hexagon Nutrition, and three SME IPOs head for listing
|
08 Jun 2026, 06:29PM
Market closes lower as crude oil prices surge amid renewed Israel-Iran tensions
Trendlyne Marketwatch |
08 Jun 2026, 04:09PM
Lupin expects normalization by September quarter
|
17 Apr 2020